GNUV201
GNUV201 is a PD-1 inhibitor with cross-reactivity in humans, mice and monkeys, which effectively blocks the PD-1/PD-L1 interaction. GNUV201 activates T cells and restores their anti-tumor activity, effectively inducing tumor regression. GNUV201 can be used in the research of related diseases such as colorectal cancer, melanoma, pancreatic cancer and colon cancer.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
製品説明
Species Reactivity
Human
体外実験
GNUV201 and its chimeric precursors bind to CHO cells expressing human PD-1 (EC50=117 pM) and CHO cells expressing mouse PD-1 (EC50=203 pM) with comparable affinities[1].
GNUV201 (15 min, 1 h) blocks the human PD-1/PD-L1 interaction in flow cytometry-based assays with an IC50 of 9.9 nM; it also blocks the murine PD-1/PD-L1 interaction with an IC50 of 6.7 nM[1].
GNUV201 blocks the interaction between human PD-1/PD-L1 in luciferase reporter gene assays, with an IC50 value of 6.3 nM[1].
GNUV201 cross-reacts with mouse PD-1 (EC50=32 pM) and human PD-1 (EC50=28 pM). It has a slower dissociation rate than Keytruda, and exhibits significantly higher binding affinity under acidic pH conditions (Kd=0.9 nM; pH=6.0)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
体内実験
GNUV201 inhibits tumor growth in the MC38/hPD-1 knock-in mouse colon cancer model[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (female, 7 weeks old, subcutaneous implantation of 1×106 MC38 murine colorectal cancer cells)[1]
-
Dosage:1 mg/kg; 3 mg/kg; 10 mg/kg
-
Administration:i.p.; twice weekly; 2-3 weeks
-
Result:Exhibited dose-dependent tumor growth inhibition with 24% TGI at 1 mg/kg, 59% TGI at 3 mg/kg, and 73% TGI on day 15 post-treatment.
Achieved statistically significant improvement in overall survival, with ~20% of mice surviving without tumor growth at 10 mg/kg.
遺伝子ID
アクセッション番号
Target
PDCD1/PD-1/CD279
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Product Image
アプリケーション
ELISA, FACS, Functional assay
化学情報
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
GNUV201 関連分類
HY-P992357 関連分類
Powered by Bioz